Indication
Atherosclerosis Obliterans
1 clinical trial
2 products
Product
CLBS12Product
SOCClinical trial
A Prospective, Open Label, Controlled, Randomized, Multicenter Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI) Due to Arteriosclerosis Obliterans (ASO) With a Single-arm Substudy to Assess the Safety and Potential Efficacy of CLBS12 in Patients With CLI Due to Buerger's Disease (BD)Status: Completed, Estimated PCD: 2022-05-19